AI Project Extended to Enhance Predictions for Drug-Resistant Epilepsy
Researchers at King's College London, led by Professor Mark Richardson, have secured further funding to extend their AI-driven project aimed at identifying risk factors for drug-resistant epilepsy. The project, supported by the Epilepsy Research Institute and Angelini Pharma, will continue for an additional 16 months.
The team has developed advanced AI tools to analyze electronic health records (EHRs) from NHS hospitals. They have already annotated records of 5,556 epilepsy patients and are set to analyze an additional 4,774 records. This large-scale data analysis seeks to uncover previously unidentified risk factors for refractory epilepsy, a condition where seizures persist despite medication.
The extension will allow researchers to expand their dataset and refine AI methodologies, with a goal of analyzing up to 30,000 patient records across three London hospitals. This effort aims to provide deeper insights into the predictors of refractory epilepsy, potentially leading to new prevention strategies and personalized treatment plans.
The Epilepsy Research Institute will continue to oversee the grant and project management. This initiative highlights the collaborative effort to advance epilepsy research through innovative AI technologies and extensive data analysis.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 5 AKASA Launches Autonomous AI Platform for Inpatient Coding Oct 5 XtalPi Advances Hair Loss Drug Into IND Enabling Studies Oct 5 Signia Launches MaX AI Hearing Aid Platform in US Oct 5 Viome Signs Agreement to Explore Molecular AI Model in Bhutan Oct 5 Quotient Sciences and Acesion Apply AI to Atrial Fibrillation DrugsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
HealthIQ Solutions and Eirion.ai Partner on Predictive AI for Remote Care
AI in Clinical Trials Market Forecast to Reach USD 7.32 Billion by 2034
Atman Health Wins ARPA-H Award to Build Heart Failure AI
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Daily AI Brief: the AI news that matters, in your inbox.